Halozyme Therapeutics (HALO)
NASDAQ:HALO
Want to see HALO full AI Analyst Report?
Halozyme (HALO) Ownership Overview
1.20% Insiders
27.48% Mutual Funds
27.60% Other Institutional Investors
28.35% ETFs
15.36% Public Companies and Individual Investors
The ownership structure of Halozyme (HALO) stock is a mix of institutional, retail, and individual investors. Approximately 83.43% of the company’s stock is owned by Institutional Investors, 1.20% is owned by Insiders, and 15.36% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
Mar 10, 2026 | xxxxxxxxxxxxx | $1955137 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Mar 31, 2024 | xxxxxxxxxxxxx | $33053656 | |
Mar 31, 2024 | xxxxxxxxxxxxx | $556723 | |
Mar 31, 2024 | xxxxxxxxxxxxx | $28740250 | |
Mar 31, 2024 | xxxxxxxxxxxxx | $261687 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 12,914,403 | Institution | 10.89% | 882,312,013 | |
| 10,237,950 | Institution | 8.63% | 699,456,744 | |
| 9,133,567 | Institution | 7.70% | 624,005,297 | |
| 3,539,756 | Institution | 2.98% | 241,836,130 | |
| 3,205,964 | Institution | 2.70% | 219,031,460 | |
| 1,395,000 | Institution | 1.18% | 95,306,400 | |
| 1,368,627 | Institution | 1.15% | 93,504,597 | |
| 1,175,910 | Institution | 0.99% | 80,338,171 | |
| 1,175,300 | Institution | 0.99% | 80,296,496 | |
| 1,101,354 | Institution | 0.93% | 75,244,505 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,133,567 | Institution | 7.70% | 624,005,297 | |
| 3,205,964 | Institution | 2.70% | 219,031,460 | |
| 1,175,910 | Institution | 0.99% | 80,338,171 | |
| 1,175,300 | Institution | 0.99% | 80,296,496 | |
| 1,101,354 | Institution | 0.93% | 75,244,505 | |
| 1,094,930 | Institution | 0.92% | 74,805,618 | |
| 1,027,105 | Institution | 0.87% | 70,171,814 | |
| 857,921 | Institution | 0.72% | 58,613,163 | |
| 775,438 | Institution | 0.65% | 52,977,924 | |
| 760,014 | Institution | 0.64% | 51,924,156 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,200,163 | Institution | 3.54% | 138,017,356 | |
| 3,978,750 | Institution | 3.35% | 282,212,738 | |
| 3,737,645 | Institution | 3.15% | 241,563,996 | |
| 2,724,480 | Institution | 2.30% | 176,083,142 | |
| 1,524,978 | Institution | 1.29% | 98,559,328 | |
| 1,410,629 | Institution | 1.19% | 93,679,872 | |
| 1,313,736 | Institution | 1.11% | 84,906,758 | |
| 1,139,003 | Institution | 0.96% | 80,789,483 | |
| 880,430 | Institution | 0.74% | 60,150,978 | |
| 858,359 | Institution | 0.72% | 60,883,404 |
FAQ
Who Owns Halozyme Therapeutics (HALO)?
According to the latest TipRanks data, approximately 27.60% of the company's stock is held by institutional investors, 1.20% is held by insiders, and 15.36% is held by retail investors.
What percentage of Halozyme Therapeutics (HALO) stock is held by institutional investors?
According to the latest TipRanks data, approximately 27.60% of Halozyme Therapeutics (HALO) stock is held by institutional investors.
What percentage of Halozyme Therapeutics (HALO) stock is held by retail investors?
According to the latest TipRanks data, approximately 15.36% of Halozyme Therapeutics (HALO) stock is held by retail investors.
Who owns the most shares of Halozyme Therapeutics (HALO)?
iShares owns the most shares of Halozyme Therapeutics (HALO).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.